From prospective biobanking to precision medicine: BIO-RAIDs - an EU study protocol in cervical cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Ngo, Charlotte ^a,j   Samuels, Sanne ^b   Bagrintseva, Ksenia ^a   Slocker, Andrea ^c   Hupé, Philippe ^a,d,e,f   Kenter, Gemma ^b   Popovic, Marina ^g   Samet, Nina ^h   Tresca, Patricia ^a   von der Leyen, Heiko ⁱ   Deutsch, Eric ^c   Rouzier, Roman ^a   Belin, Lisa ^a   Kamal, Maud ^a   Scholl, Suzy ^a  

^a INSTITUT CURIE   (France)

^b Netherlands Cancer Institute Antoni van Leeuwenhoek (NKI AVL)   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d INSERM U900   (France)

^e PSL RESEARCH UNIVERSITY   (France)

^f INSTITUT CURIE   (France)

^g Institut of Oncology of Vojvodina (IOV)   (France)

^h Institute of Oncology of Republic of Moldova   (France)

ⁱ Hannover Clinical Trial Center (HCTC) GmbH   (France)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

Biobanking; Cervical cancer; Clinical trial operations; HPV typing; International trial; Molecular profiling; Next generation sequencing; Patient stratification; Precision medicine; Prospective European biobanking study; Quality control of pelvic radiotherapy; Reverse phase protein array; Targeted therapy; Tumor micro environment

Indexed keywords

ARTICLE; BIOINFORMATICS; BRACHYTHERAPY; CANCER PROGNOSIS; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPEAN UNION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NEXT GENERATION SEQUENCING; PRACTICE GUIDELINE; PROTEIN MICROARRAY; QUALITY OF LIFE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; ADOLESCENT; ADULT; AGED; BIOPSY; BLOOD; CLINICAL TRIAL; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; UTERINE CERVIX TUMOR;

TUMOR MARKER;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; BIOPSY; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; PRECISION MEDICINE; UTERINE CERVICAL NEOPLASMS;

EID: 84946214063     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1801-0     Document Type: Article

References (26)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014. doi: 10.1002/ijc.29210.
2. Arbyn M, Antoine J, Magi M, Smailyte G, Stengrevics A, Suteu O, et al. Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania. Int J Cancer. 2011;128(8):1899-907. doi: 10.1002/ijc.25525.
3. Zur Hausen H. The search for infectious causes of human cancers: where and why. Virology. 2009;392(1):1-10. doi: 10.1016/j.virol.2009.06.001.
4. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009;105(2):107-8. doi: 10.1016/j.ijgo.2009.02.009.
5. Choi SH, Kim SH, Choi HJ, Park BK, Lee HJ. Preoperative magnetic resonance imaging staging of uterine cervical carcinoma: results of prospective study. J Comput Assist Tomogr. 2004;28(5):620-7.
6. Dhoot NM, Kumar V, Shinagare A, Kataki AC, Barmon D, Bhuyan U. Evaluation of carcinoma cervix using magnetic resonance imaging: correlation with clinical FIGO staging and impact on management. J Med Imaging Radiat Oncol. 2012;56(1):58-65. doi: 10.1111/j.1754-9485.2011.02333.x.
7. Kraljevic Z, Viskovic K, Ledinsky M, Zadravec D, Grbavac I, Bilandzija M, et al. Primary uterine cervical cancer: correlation of preoperative magnetic resonance imaging and clinical staging (FIGO) with histopathology findings. Coll Antropol. 2013;37(2):561-8.
8. Rose PG. Chemoradiotherapy: the new standard care for invasive cervical cancer. Drugs. 2000;60(6):1239-44.
9. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144-53. doi: 10.1056/NEJM199904153401502.
10. Tewari KS, Sill MW, Long 3rd HJ, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734-43. doi: 10.1056/NEJMoa1309748.
11. Duenas-Gonzalez A, Zarba JJ, Patel F, Alcedo JC, Beslija S, Casanova L, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011;29(13):1678-85. doi: 10.1200/JCO.2009.25.9663.
12. Baalbergen A, Veenstra Y, Stalpers L. Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. Cochrane Database Syst Rev. 2013;1:CD006248. doi: 10.1002/14651858.CD006248.pub3.
13. Alleyne-Mike K, van Wijk L, Hunter A. A retrospective review of patients with stage IB2 cervical cancer treated with radical radiation versus radical surgery as a primary modality. Int J Gynecol Cancer. 2013;23(7):1287-94. doi: 10.1097/IGC.0b013e31829fb834.
14. Bansal N, Herzog TJ, Shaw RE, Burke WM, Deutsch I, Wright JD. Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. Am J Obstet Gynecol. 2009;201(5):485 e1-9. doi: 10.1016/j.ajog.2009.06.015.
15. Ryu HS, Kang SB, Kim KT, Chang KH, Kim JW, Kim JH. Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea: results of a multicenter retrospective Korean study (KGOG-1005). Int J Gynecol Cancer. 2007;17(1):132-6. doi: 10.1111/j.1525-1438.2007.00803.x.
16. Scatchard K, Forrest JL, Flubacher M, Cornes P, Williams C. Chemotherapy for metastatic and recurrent cervical cancer. Cochrane Database Syst Rev. 2012;10:CD006469. doi: 10.1002/14651858.CD006469.pub2.
17. McCormack M, Lake F. Promising new developments in cervical cancer. Future Oncol. 2014;10(9):1541-4. doi: 10.2217/fon.14.63.
18. de la Rochefordiere A, Kamal M, Floquet A, Thomas L, Petrow P, Petit T et al. PIK3CA pathway mutations predictive of poor response following Standard radio chemotherapy +/- Cetuximab in cervical cancer patients. Clin Cancer Res. 2015. doi: 10.1158/1078-0432.CCR-14-2368.
19. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ et al. Landscape of genomic alterations in cervical carcinomas. Nature. doi: 10.1038/nature12881.
20. Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013;119(21):3776-83. doi: 10.1002/cncr.28288.
21. McIntyre JB, Wu JS, Craighead PS, Phan T, Kobel M, Lees-Miller SP, et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol. 2013;128(3):409-14. doi: 10.1016/j.ygyno.2012.12.019.
22. Servant N, Romejon J, Gestraud P, La Rosa P, Lucotte G, Lair S, et al. Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial. Front Genet. 2014;5:152. doi: 10.3389/fgene.2014.00152.
23. Haie-Meder C, Potter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005;74(3):235-45. doi: 10.1016/j.radonc.2004.12.015.
24. Breunig J, Hernandez S, Lin J, Alsager S, Dumstorf C, Price J et al. A system for continual quality improvement of normal tissue delineation for radiation therapy treatment planning. Int J Radiat Oncol Biol Phys. 2012 August 1; 83(5): e703-e708.
25. Dimopoulos JC, De Vos V, Berger D, Petric P, Dumas I, Kirisits C et al. Interobserver comparison of target delineation for MRI-assisted cervical cancer brachytherapy: application of the GYN GEC-ESTRO recommendations. Radiother Oncol. 2009;91:166-172.
26. Petersen RP, Truong PT, Kader HA, Berthelet E, Lee JC, Hilts ML et al. Target volume delineation for partial breast radiotherapy planning: Clinical characteristics associated with low interobserver concordance. Int J Radiat Oncol Biol Phys. 2007;69:41-8.